SRPT Sarepta Therapeutics
- 117.520
- +0.690+0.59%
Sarepta Therapeutics News
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 9 Analysts
9 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table encapsulates
Catalyst Watch: HP Enterprise Event, Walmart+ Week, Pure Storage Buzz, and Triple-witching Volatility
Sarepta Therapeutics Is Maintained at Outperform by BMO Capital
Sarepta Therapeutics Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $170
BMO Capital analyst Kostas Biliouris maintains $Sarepta Therapeutics(SRPT.US)$ with a buy rating, and maintains the target price at $170.According to TipRanks data, the analyst has a success rate of 3
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival -- Barrons.com
By Josh Nathan-Kazis A second failure of a late-stage trial testing a gene therapy to treat Duchenne muscular dystrophy is bad news for patients, but Wall Street analysts say it could be good new for
Express News | Sarepta Therapeutics Shares up 3.8% After Pfizer's Duchenne Gene Therapy Trial Miss; Pfizer Last Down 1%
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $166
BofA Securities analyst Tazeen Ahmad maintains $Sarepta Therapeutics(SRPT.US)$ with a buy rating, and maintains the target price at $166.According to TipRanks data, the analyst has a success rate of 4
4 Stocks to Watch on Thursday: ADBE, KMB and More
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $157 to $185
On Jun 13, major Wall Street analysts update their ratings for $Sarepta Therapeutics(SRPT.US)$, with price targets ranging from $157 to $185.BofA Securities analyst Tazeen Ahmad maintains with a buy r
Pfizer's Gene-therapy Trial Failure Boosts Sarepta's Stock
By Eleanor Laise Sarepta's gene therapy for Duchenne muscular dystrophy could soon get expanded label from FDA Shares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a pote
Express News | Sarepta Therapeutics Shares up About 4% Premarket After Pfizer's Duchenne Gene Therapy Trial Miss
Pfizer's Duchenne Pain Seen As Sarepta's Gain -- Market Talk
0748 ET - The failure of Pfizer's proposed gene therapy for Duchenne muscular dystrophy in a late-stage trial is a plus for Sarepta Therapeutics and its Elevidys gene therapy. Analysts at Mizuho and W
S&P 500 Futures Up In Premarket Trading; Broadcom, Tesla Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Broadcom Inc. (AVGO) was up 13.8% in pre-market tra
Sarepta Gains After Pfizer's Late-stage Setback for Duchenne Therapy
Daily short sale tracking: Sirius XM's short volume increased by 13 million, with a short sale ratio of 16%
Sirius XM(SIRI.US) ranked top of the list had the largest change in short volume (13.85 million shares), and the short volume ratio of Masimo(MASI.US) reached 48.22%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Express News | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?
Sarepta Therapeutics Initiated at Overweight by Piper Sandler
Sarepta Therapeutics Initiated at Overweight by Piper Sandler
Express News | Piper Sandler Initiates Coverage On Sarepta Therapeutics With Overweight Rating, Announces Price Target of $157
Analysis
Price Target
No Data
